United States · Bill · HR
H.R. 4619 (116th)
Pharmaceutical REPAI Act
Introduced
8 October 2019
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
7 April 2025
Summary
Pharmaceutical Rebates for Excessive Pricing Above Inflation Act or the Pharmaceutical REPAI Act This bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under the Medicare prescription drug benefit that cost $100 or more and for which the average manufacturer price increases faster than inflation.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 8 October 2019
Introduced in House (PDF)
Introduced in House · EN · 8 October 2019
Introduced in House
summary · EN · 8 October 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/4619
- Open data entity: https://api.congress.gov/v3/bill/116/hr/4619